rosiglitazone new england journal of medicine

Azithromycin is an inexpensive, generic antibiotic available in tablet form and suitable for room-temperature storage. In addition to a reduction in sepsis, the study found a lower risk of maternal endometritis (uterine infection), hospital readmission and unscheduled medical visits among women who received azithromycin. “We saw such a significant reduction in the incidence of sepsis with azithromycin that we stopped enrolling new participants early to ensure that as many women as possible could benefit from our findings as soon as possible.” Antoinette Tshefu Kitoto, Professor of Public Health at Kinshasa School of Public Health and International Principal Investigator of the UNC-Democratic Republic of the Congo site. “Sepsis is one of the leading causes of maternal death worldwide and there is urgent need for low-cost, effective interventions,” said Prof. However, an interim analysis found the treatment had a significant beneficial effect, and enrollment was halted early for maternal effectiveness after approximately 29,000 women were studied. The study was designed to include 34,000 women in seven low- and middle-income countries who received a single dose of azithromycin or placebo during childbirth. Given the nearly 6 million cases of maternal sepsis per year, 3 the A-PLUS study results suggest that up to 2 million cases of maternal sepsis per year could be prevented with this readily available, affordable medicine. When a combination of sepsis and death was analyzed, there was a 33% reduction. 2 This randomized, placebo-controlled study found that a single dose of azithromycin reduces the occurrence of maternal sepsis by approximately 35%. The World Health Organization (WHO) estimates sepsis due to obstetric infection is the third most common cause of maternal mortality globally. Sepsis is a life-threatening condition caused by the body’s extreme response to infection and can lead to organ failure and death. We thank the thousands of women and their care providers in seven countries who agreed to participate in the study even in the midst of a pandemic.” “This multinational study is an exemplar of what can be accomplished through team science - connecting academic researchers around the world with NIH experts and private foundations, like the Bill & Melinda Gates Foundation, to advance global health breakthroughs. Julie Gerberding, CEO of the Foundation for the National Institutes of Health (FNIH). “The A-PLUS study has remarkable potential to protect maternal health and represents a significant advancement, especially for women who cannot access modern obstetrical care,” said Dr. 1 The study, called the Azithromycin Prevention in Labor Use Study (A-PLUS), found that one dose of azithromycin, a low-cost, generic, oral antibiotic, given during labor to women planning to deliver vaginally in low- and middle-income countries, can prevent life-threatening sepsis. 9, 2023 - The Foundation for the National Institutes of Health (FNIH) today announced that The New England Journal of Medicine (NEJM) has published the results of a study of antibiotic treatment to protect maternal health in resource-limited settings that could benefit up to 2 million women per year. The Deeda Blair Research Initiative for Disorders of the Brain.Trailblazer Prize for Clinician-Scientists.Partnership For Accelerating Cancer Therapies (PACT).Master Protocol for Treatment of Non-Small Cell Lung Cancer (Lung-MAP).

Azithromycin Prevention in Labor Use Study (A-PLUS).Alzheimer’s Disease Neuroimaging Initiative (ADNI).Accelerating COVID-19 Therapeutic Interventions & Vaccines (ACTIV).Accelerating Medicines Partnership® (AMP®).

Rosiglitazone new england journal of medicine